Tech Stock News
Sunday, September 25, 2022
CEL-SCI Corporation (NYSEAMERICAN: CVM) has issued a letter to shareholders addressing the confusion about the third phase study results in newly diagnosed advanced primary head and neck cancer released last week. Multikine demonstrated statistical significance in five-year survival benefit The company said that its Multikine immunotherapy showed statistically significant five-year […]
CEL-SCI Corporation (NYSE American: CVM) is ready to discuss its Phase 3 head and neck cancer trial results after the Annual Shareholder Meeting. The study was featuring Multikine, investigational cancer immunotherapy known to have 14 natural human cytokines. The results indicate a significant production of 14.1% 5-year survival benefit (62.7% […]